1. Search Result
Search Result
Results for "

Anxiety disorders

" in MedChemExpress (MCE) Product Catalog:

183

Inhibitors & Agonists

2

Screening Libraries

5

Peptides

9

Natural
Products

19

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-122272
    Paroxetine
    Maximum Cited Publications
    17 Publications Verification

    BRL29060

    Serotonin Transporter Adrenergic Receptor P2X Receptor Apoptosis Neurological Disease Cancer
    Paroxetine is an oral inhibitor that falls under the category of selective serotonin reuptake inhibitors (SSRIs). Paroxetine is also a very weak norepinephrine (NE) reuptake inhibitor, capable of inducing cell apoptosis and having anti-tumor activity. Paroxetine has antidepressant, anti-anxiety, and pain-relieving effects, and it can help improve conditions like obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual anxiety, and chronic headaches .
    Paroxetine
  • HY-B0161A
    Duloxetine hydrochloride
    10+ Cited Publications

    (S)-Duloxetine hydrochloride; LY-248686 hydrochloride

    Serotonin Transporter Neurological Disease Cancer
    Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
    Duloxetine hydrochloride
  • HY-B1115A
    Buspirone
    3 Publications Verification

    5-HT Receptor Dopamine Receptor Reactive Oxygen Species (ROS) Neurological Disease Cancer
    Buspirone is an orally active 5-HT1A receptor agonist, and a dopamine D2 autoreceptorsant antagonist. Buspirone is an anxiolytic agent, and can be used for the generalized anxiety disorder research .
    Buspirone
  • HY-B0161
    Duloxetine
    10+ Cited Publications

    LY248686

    Serotonin Transporter Neurological Disease Cancer
    Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
    Duloxetine
  • HY-B0548
    Hydroxyzine
    1 Publications Verification

    Histamine Receptor Inflammation/Immunology Endocrinology
    Hydroxyzine, a benzodiazepine antihistamine agent, acts as an orally active histamine H1-receptor and serotonin antagonist. Hydroxyzine has anxiolytic effect and can be used for the research of generalised anxiety disorder .
    Hydroxyzine
  • HY-122422

    5-HT Receptor Others
    Gepirone is a selective and affinitive 5-HT1A agonist. Gepirone binds selectively to 5-HT1A receptor binding site. Gepirone acts as an antidepressant agent can be used for anxiety and major depressive disorder research .
    Gepirone
  • HY-B0548A
    Hydroxyzine dihydrochloride
    1 Publications Verification

    Histamine Receptor Inflammation/Immunology Endocrinology
    Hydroxyzine dihydrochloride, a benzodiazepine antihistamine agent, acts as a orally active histamine H1-receptor and serotonin antagonist. Hydroxyzine dihydrochloride has anxiolytic effect and can be used forthe research of generalised anxiety disorder .
    Hydroxyzine dihydrochloride
  • HY-118901

    Ensidon; G-33040

    Sigma Receptor Neurological Disease
    Opipramol (Ensidon) is an atypical tricyclic antidepressant (TCA). Opipramol acts primarily as a sigma (σ) receptor agonist and can potently interact with sigma recognition sites with a Ki value of 50 nM. Opipramol can be used for the research of generalized anxiety disorder (GAD) .
    Opipramol
  • HY-136684
    BrBzGCp2
    4 Publications Verification

    S-p-Bromobenzylglutathione cyclopentyl diester

    Glyoxalase (GLO) Neurological Disease Cancer
    BrBzGCp2 is a Glyoxalase 1 (GLO1) inhibitor, with a GC50 of 4.23 μM in HL-60 cells. BrBzGCp2 possesses antitumor and neuroprotective activity .
    BrBzGCp2
  • HY-15522
    WAY-267464
    2 Publications Verification

    Oxytocin Receptor Neurological Disease
    WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .
    WAY-267464
  • HY-105042

    Selanc; TP-7

    GABA Receptor Neurological Disease
    Selank (Selanc; TP-7) is a GABAA receptor modulator with anxiolytic activity. Selank allosterically modulates the specific binding of GABA to GABAA receptors and alters the affinity of endogenous ligands for these receptors. Selank reduces elevated anxiety levels, attenuates stress-induced exacerbation of anxiety, and produces a synergistic anxiolytic effect with diazepam. Selank can be used in the research of anxiety disorders .
    Selank
  • HY-109164

    AGN-241751; GATE-251

    iGluR Neurological Disease
    Zelquistinel (AGN-241751) is the orally active N-methyl-D-aspartate (NMDA) receptor partial agonist used for the research of depression, anxiety and other related psychiatric disorders .
    Zelquistinel
  • HY-160236

    Drug Metabolite Neurological Disease
    3-(3-Sulfooxyphenyl) propanoic acid is a metabolite of Echinacoside (HY-N0020). It promotes neural, psychological and brain health, enhances the proliferation, function and activity of brain cells, and facilitates extinction learning. 3-(3-Sulfooxyphenyl) propanoic acid can be used in research related to anxiety disorders, post-traumatic stress disorder, extinction learning deficits, autism, as well as neurodegenerative diseases including Parkinson's disease and Alzheimer's disease .
    3-(3-Sulfooxyphenyl)propanoic acid
  • HY-103505

    GABA Receptor Neurological Disease
    CL 218872 is an orally active and selective ligand for the benzodiazepine receptor subtype BZ1. CL 218872 exhibits anxiolytic, sedative and anticonvulsant activities. CL 218872 can be used in researches of anxiety related disorders and epilepsy .
    CL 218872
  • HY-108626

    NCGC84

    Neuropeptide S Receptor Neurological Disease
    ML154 (NCGC84) is a selective, brain-penetrant and non-peptide neuropeptide S receptor (NPSR) antagonist with a pA2 of 9.98. ML154 potently inhibits NPS-stimulated cellular calcium, cAMP, and ERK phosphorylation responses with IC50 values of 36.5 nM, 22.1 nM, and 9.3 nM, respectively .
    ML154
  • HY-B1752
    Quinpirole
    4 Publications Verification

    LY 171555; (-)-LY 141865

    Dopamine Receptor Calcium Channel Bcl-2 Family iGluR Apoptosis Neurological Disease
    Quinpirole (LY 171555; (-)-LY 141865) is a D2/D3 dopamine receptor agonist and a CaV1.3 calcium channel modulator. Quinpirole normalizes dendritic spine density in dopamine-depleted striatum, upregulates the protein expression of BCL2 and GluR2, downregulates the protein expression of BAX, and delays the onset of seizures. Quinpirole enhances learning and memory, inhibits neuronal apoptosis (apoptosis), and induces anxiety-like, stereotyped, and compulsive behaviors. Quinpirole disrupts prepulse inhibition in rhesus monkeys, enhances the activity of paraventricular thalamic neurons to promote recovery from Isoflurane anesthesia, and alters the composition of the gut microbiota in rats. Quinpirole can be used in research related to dyskinesia, pain, epilepsy, and neurological disorders including anxiety disorder, obsessive-compulsive disorder, and schizophrenia .
    Quinpirole
  • HY-19490

    AQW-051

    nAChR Neurological Disease
    VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pKD value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety .
    VQW-765
  • HY-147403S

    JNJ-61393215

    Orexin Receptor (OX Receptor) Isotope-Labeled Compounds Neurological Disease
    Tebideutorexant is an OX1R-selective inhibitor with oral bioavailability and blood-brain barrier permeability, with human OX1R pKi 8.17 and rat OX1R pKi 8.13.Tebideutorexant selectively modulates OX1R, with no significant functional effect on OX2R. Tebideutorexant can be used for the research of panic and anxiety disorders .
    Tebideutorexant
  • HY-122487

    BHV-4157

    mGluR Neurological Disease Cancer
    Troriluzole, a third-generation, tripeptide proagent of Riluzole (HY-B0211), is an orally active glutamate modulator. Troriluzole reduces synaptic glutamate level and increases the synaptic glutamate absorption. Troriluzole has the potential for Alzheimer disease and generalized anxiety disorder (GAD) .
    Troriluzole
  • HY-108679
    WAY-267464 hydrochloride
    2 Publications Verification

    Oxytocin Receptor Neurological Disease
    WAY-267464 (hydrochloride) is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 (hydrochloride) can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 (hydrochloride) can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .
    WAY-267464 hydrochloride
  • HY-134188

    Orexin Receptor (OX Receptor) Neurological Disease
    JNJ-54717793, as a brain penetrant, is an orally active, selective and high affinity orexin-1 receptor (OX1R) antagonist (plasma EC50=85 ng/mL). The Ki values of JNJ-54717793 for hOX1R (human OX1R) and hOX2R are 16 nM and 700 nM, respectively. JNJ-54717793 is a potent compound of anxiety disorders .
    JNJ-54717793
  • HY-107624
    ATC0175
    1 Publications Verification

    MCHR1 (GPR24) Neurological Disease
    ATC0175 is a potent, selective and orally active melanin-concentrating hormone 1 recepter antagonist with IC50s of 13.5, >10000 nM for MCH1R, MCH2R, respectively. ATC0175 shows antidepressant effects and anxiolytic effects in animal models. ATC0175 has the potential for the research of depression and/or anxiety disorders .
    ATC0175
  • HY-78509

    Biochemical Assay Reagents Drug Intermediate Neurological Disease
    Dibenzosuberone belongs to the family of tricyclic antidepressant drugs, commonly referred to as Tricyclic antidepressants (TCAs), and is widely used in research on migraine, tension headaches, anxiety disorders, and schizophrenia. Dibenzosuberone is also a key intermediate in the synthesis of various active pharmaceutical ingredients (APIs), such as Amitriptyline (HY-B0527), Nortriptyline (HY-118620), Noxiptiline or Cyproheptadine (HY-B1622) .
    Dibenzosuberone
  • HY-N9502

    Endogenous Metabolite Neurological Disease
    Linalool oxide is a monoterpene and found in aromatic plant essential oils and is a secondary metabolite in elongating wheat plants. Linalool oxide has antinociceptive, anticonvulsant, and anxiolytic activity. Linalool oxide can be used for the research of pain, epilepsy, anxiety disorders .
    Linalool oxide
  • HY-19686

    TVX Q 7821 free base

    5-HT Receptor Neurological Disease
    Ipsapirone (TVX Q 7821) is an anxiolytic compound and a 5-HT1A receptor partial agonist. Ipsapirone (TVX Q 7821) also exhibits 5-HT1A receptor antagonistic effect, and only at high doses it can also produce an inhibitory effect on 5-HT2 and the α1-adrenergic function .
    Ipsapirone
  • HY-B1316

    Fungal Infection Neurological Disease
    Trimetozine is an Antifungal agent and sedative. Trimetozine exhibits antibacterial activity against Candida albicans, Candida glabrata, and Miconazole (HY-B0454)-resistant Candida glabrata cultures. Trimetozine exerts a sedative effect. Trimetozine can be used in research related to candidiasis and anxiety disorders .
    Trimetozine
  • HY-148325

    nAChR Neurological Disease
    α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .
    α7 Nicotinic receptor agonist-1
  • HY-116780A

    Cytochrome P450 Neurological Disease
    Prothipendyl hydrochloride is a tricyclic azaphenothiazine neuroleptic agent. Prothipendyl hydrochloride is a substrate of the CYP isozymes CYP1A2, CYP2D6, CYP2C19 and CYP3A4. Prothipendyl hydrochloride has sedating and psychomotorically damping effects. Prothipendyl hydrochloride can be used for psychomotoric agitation, sleep disorder and anxiety research .
    Prothipendyl hydrochloride
  • HY-101665

    (+)-RP-59037; IP-456; RP-62955

    GABA Receptor Neurological Disease
    Pagoclone is an active (+)-enantiomer of the racemate RP 59037. Pagoclone is a partial GABA(A) receptor agonist used for the treatment of panic and anxiety disorders.
    Pagoclone
  • HY-19872

    GABA Receptor Neurological Disease
    AZD6280 is a selective GABAA(α2/3) receptor modulator, used for treatment of generalized anxiety disorder.
    AZD6280
  • HY-122272R

    BRL29060 (Standard)

    Serotonin Transporter Adrenergic Receptor P2X Receptor Apoptosis Reference Standards Neurological Disease Cancer
    Paroxetine (Standard) is the analytical standard of Paroxetine. This product is intended for research and analytical applications. Paroxetine is an oral inhibitor that falls under the category of selective serotonin reuptake inhibitors (SSRIs). Paroxetine is also a very weak norepinephrine (NE) reuptake inhibitor, capable of inducing cell apoptosis and having anti-tumor activity. Paroxetine has antidepressant, anti-anxiety, and pain-relieving effects, and it can help improve conditions like obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual anxiety, and chronic headaches .
    Paroxetine (Standard)
  • HY-B0161S

    Isotope-Labeled Compounds Serotonin Transporter Neurological Disease
    Duloxetine-d7 ((S)-Duloxetine-d7) is the deuterium labeled Duloxetine. Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
    Duloxetine-d7
  • HY-W001692

    DOV 273547

    GABA Receptor Neurological Disease
    Ocinaplon (DOV 273547) is an orally active positive allosteric modulator of GABAA receptor, with an EC50 ranging from 3.07 μM (α1β2γ2 subtype) to 10.03 μM (α1β2γ3 subtype). Ocinaplon enhances GABA-stimulated chloride currents across multiple GABAA receptor subtypes, with varying potency between different subtypes. Ocinaplon exerts anxiolytic and anticonvulsant effects, and causes motor impairment at high doses. Ocinaplon can be used for research on generalized anxiety disorder .
    Ocinaplon
  • HY-117526

    Serotonin Transporter Neurological Disease
    (-)-Mesembrine is a serotonin transporter (SERT) inhibitor. (-)-Mesembrine inhibits serotonin reuptake. (-)-Mesembrine exerts anxiolytic, mood-enhancing and anti-addictive effects. (-)-Mesembrine is applicable to research on mild-to-moderate depression, anxiety disorders and stress-related conditions .
    (-)-Mesembrine
  • HY-128174

    Beta-CCM; Ro 22-7497

    GABA Receptor Neurological Disease
    β-CCM is a benzodiazepine receptor inverse agonist with anxiogenic and proconvulsant effects. β-CCM enhances emotional reactivity and reduces vulnerability to interference in spatial working memory tasks. β-CCM can be used for research on anxiety-related disorders .
    β-CCM
  • HY-116076

    5-HT Receptor Neurological Disease
    S-15535 is a highly selective 5-HT1A receptor ligand. S-15535 is an antagonist of postsynaptic 5-HT1A receptors and an agonist of presynaptic 5-HT1A receptors. S-15535 can be used in research on psychiatric disorders, such as anti-anxiety .
    S-15535
  • HY-147306

    NO Synthase Neurological Disease
    ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation .
    ZLc-002
  • HY-W039283

    MCHR1 (GPR24) Neurological Disease Cancer
    MCH-1 antagonist 2 (l-BROMO-2,4-DIFLUORO-5-NITROBEN-ZENE) is a melanin concentrating hormone-1 (MCH1) receptor-selective 4-aryl piperidine. MCH-1 antagonist 2 can be used for the research of depression, anxiety, obesity, urge incontinence, urinary incontinence, major depression, bipolar disorder, agoraphobia, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress disorder, urinary frequency, urinary urgency, nocturia, enuresis, bulimia, bulimia nervosa, anorexia nervosa, major depressive disorder, dysthymic disorder, bipolar 1 and 2 disorders, schizoaffective disorder, cognitive disorders with depressed mood, personality disorders, insomnia, hypersomnia, narcolepsy, circadian rhythm sleep disorder, nightmare disorder, sleep terror disorder, sleepwalking disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, overactive bladder .
    MCH-1 antagonist 2
  • HY-138693

    FAAH Neurological Disease
    ST4070 is a potent, orally active, and selective reversible fatty acid amide hydrolase (FAAH) inhibitor. ST4070 increases endocannabinoid (eCB) brain levels and counteracts neuropathic pain in animal models. ST4070 enhances the endogenous eCB tone in specific brain regions engaged in emotional control, and induces remarkable anxiolytic-like behaviours in rodents. ST4070 can be used for neuropathic pain and anxiety disorders research .
    ST4070
  • HY-P10405A

    Dopamine Receptor Neurological Disease
    TAT-D1 peptide acetate is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide acetate disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide acetate produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide acetate can be used in the research of psychostimulant addiction, depression and anxiety disorders .
    TAT-D1 peptide acetate
  • HY-148718

    5-HT Receptor Neurological Disease
    4-Chloro Trazodone hydrochloride is an isomer of Trazodone hydrochloride (HY-B0478). Trazodone hydrochloride is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors for treatment of anxiety disorders .
    4-Chloro Trazodone hydrochloride
  • HY-112567

    Adenosine Receptor Neurological Disease
    TRR469 is a positive allosteric modulator of the A1 adenosine receptor (A1AR). TRR469 significantly increases the affinity of 2-chloro N(6)-cyclopentyladenosine (CCPA) for A₁AR, increasing the number of receptors recognized by the agonist radioligand [³H]-CCPA. TRR469 shows significant effects in both anxiety and pain models. TRR469 can be used to study anxiety disorders and pain management .
    TRR469
  • HY-155205

    Cholecystokinin Receptor Neurological Disease
    GV150013X is an antagonist for cholecystokinin-2/gastrin receptor (CCK2R), with Ki of 2.29 nM. GV150013X attenuates central nervous disorders, such as anxiety and panic disorder .
    GV150013X
  • HY-110029
    Paroxetine maleate
    5+ Cited Publications

    BRL29060 maleate

    Serotonin Transporter Neurological Disease
    Paroxetine maleate is a potent and selective inhibitor of SSRI. Paroxetine maleate is used in generalized anxiety disorder, post traumatic stress disorder, premenstrual dysphoric disorder and chronic headache research .
    Paroxetine maleate
  • HY-153458

    Orexin Receptor (OX Receptor) Cardiovascular Disease Neurological Disease Metabolic Disease
    Orexin receptor modulator-1 is an orexin receptor modulator. Orexin receptor modulator-1 can be used for the research of substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension .
    Orexin receptor modulator-1
  • HY-122487A

    BHV-4157 hydrochloride

    mGluR Neurological Disease
    Troriluzole hydrochloride is a third-generation peptide precursor of Riluzole (HY-B0211) and is an orally active glutamate modulator. Troriluzole hydrochloride can reduce synaptic glutamate levels and enhance the uptake of synaptic glutamate. Troriluzole hydrochloride shows potential for treating Alzheimer's disease and Generalized Anxiety Disorder (GAD) .
    Troriluzole hydrochloride
  • HY-14128

    SB-723620

    CRFR Neurological Disease
    NBI-34041 (SB-723620) is a selective and orally active nonpeptide CRF1 receptor antagonist with an IC50 of 58.9 nM and a Ki of 4.0 nM for human CRF1 receptor. NBI-34041 has no inhibitory effect on the CRF2 receptor. NBI-34041 can be used for depression and anxiety disorders research.
    NBI-34041
  • HY-P10405

    Dopamine Receptor Neurological Disease
    TAT-D1 peptide is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide can be used in the research of psychostimulant addiction, depression and anxiety disorders .
    TAT-D1 peptide
  • HY-117046

    5-HT Receptor Histamine Receptor Adrenergic Receptor Neurological Disease
    AVN-101 is a potent, brain-penetrant and orally active 5-HT7 receptor antagonist (Ki of 153 pM), with slightly lesser potency toward 5-HT6, 5-HT2A, and 5HT-2C receptors (Ki values of 2.04 nM, 1.56  nM, and 1.17  nM, respectively). AVN-101 also exhibits a rather high affinity toward histamine H1 (Ki of 0.58 nM) and adrenergic α2A, α2B, and α2C (Ki= 0.41-3.6 nM) receptors. AVN-101 can be studied in such diseases as general anxiety disorders, depression, schizophrenia, Alzheimer’s disease, and multiple sclerosis .
    AVN-101
  • HY-10886

    Opioid Receptor Neurological Disease
    MCOPPB is an orally active and selective agonist of Nociceptin/Orphanin FQ–Receptor. MCOPPB inhibits signaling through the NOP receptor in the mouse brain. MCOPPB is used in anxiety disorders research .
    MCOPPB

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: